MX358463B - Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa. - Google Patents

Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.

Info

Publication number
MX358463B
MX358463B MX2014002031A MX2014002031A MX358463B MX 358463 B MX358463 B MX 358463B MX 2014002031 A MX2014002031 A MX 2014002031A MX 2014002031 A MX2014002031 A MX 2014002031A MX 358463 B MX358463 B MX 358463B
Authority
MX
Mexico
Prior art keywords
pyrano
thiazole
glycosidase inhibitors
inhibitors
glycosidase
Prior art date
Application number
MX2014002031A
Other languages
English (en)
Other versions
MX2014002031A (es
Inventor
Liu-Bujalski Lesley
Goutopoulos Andreas
Qui Hui
Yu Henry
Donnelly Marianne
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014002031A publication Critical patent/MX2014002031A/es
Publication of MX358463B publication Critical patent/MX358463B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nuevos compuestos de la fórmula (I), en donde R1 a R4 y X tienen el significado de acuerdo a las reivindicaciones, son inhibidores de glucosidasa, y se pueden emplear, inter alia, para el tratamiento de la enfermedad de Alzheimer.
MX2014002031A 2011-08-25 2012-08-22 Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa. MX358463B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527323P 2011-08-25 2011-08-25
PCT/US2012/051785 WO2013028715A1 (en) 2011-08-25 2012-08-22 Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors

Publications (2)

Publication Number Publication Date
MX2014002031A MX2014002031A (es) 2014-03-21
MX358463B true MX358463B (es) 2018-08-22

Family

ID=46759099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002031A MX358463B (es) 2011-08-25 2012-08-22 Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.

Country Status (22)

Country Link
US (2) US8884023B2 (es)
EP (1) EP2748171B1 (es)
JP (1) JP5893738B2 (es)
KR (1) KR102008032B1 (es)
CN (1) CN103930428B (es)
AU (1) AU2012298949B2 (es)
BR (1) BR112014004219B1 (es)
CA (1) CA2845149C (es)
DK (1) DK2748171T3 (es)
EA (1) EA022562B1 (es)
ES (1) ES2568603T3 (es)
HK (1) HK1196607A1 (es)
HR (1) HRP20160334T1 (es)
HU (1) HUE029390T2 (es)
IL (1) IL231008A (es)
MX (1) MX358463B (es)
PL (1) PL2748171T3 (es)
RS (1) RS54773B1 (es)
SG (1) SG2014009617A (es)
SI (1) SI2748171T1 (es)
WO (1) WO2013028715A1 (es)
ZA (1) ZA201400387B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201249848A (en) 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012083435A1 (en) 2010-12-23 2012-06-28 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
EP2688899B1 (en) 2011-03-24 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) * 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9199949B2 (en) 2011-06-27 2015-12-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
KR102054744B1 (ko) 2011-06-27 2019-12-11 알렉토스 테라퓨틱스 인크. 선택적인 글리코시다아제 저해제 및 이의 용도
CN103930428B (zh) * 2011-08-25 2016-05-11 默克专利有限公司 用作糖苷酶抑制剂的吡喃并[3,2-d][1,3]噻唑
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
KR20180056653A (ko) * 2015-09-18 2018-05-29 도레이 카부시키가이샤 하우징
MX2018010191A (es) 2016-02-25 2019-05-20 Asceneuron S A Inhibidores de glucosidasa.
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
KR20180132060A (ko) 2016-02-25 2018-12-11 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2021086966A1 (en) * 2019-10-29 2021-05-06 Biogen Ma Inc. Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5154954B2 (ja) * 2005-03-01 2013-02-27 サイモン フレイザー ユニバーシティ 選択的なグリコシダーゼインヒビター、インヒビターを作製する方法、およびインヒビターの使用
BRPI0706780A2 (pt) * 2006-01-30 2011-04-05 Irm Llc compostos e composições como moduladores de ppar
CN101595111A (zh) * 2006-08-31 2009-12-02 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
JP5380293B2 (ja) * 2006-08-31 2014-01-08 サイモン・フレーザー・ユニバーシティ 選択的グリコシダーゼ阻害剤およびその使用
EP2569291B1 (en) 2010-05-11 2016-04-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012083435A1 (en) 2010-12-23 2012-06-28 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
CN103930428B (zh) * 2011-08-25 2016-05-11 默克专利有限公司 用作糖苷酶抑制剂的吡喃并[3,2-d][1,3]噻唑

Also Published As

Publication number Publication date
EA201490493A1 (ru) 2014-06-30
MX2014002031A (es) 2014-03-21
AU2012298949A1 (en) 2014-01-30
US9469657B2 (en) 2016-10-18
KR102008032B1 (ko) 2019-08-06
SI2748171T1 (sl) 2016-06-30
US20140243370A1 (en) 2014-08-28
IL231008A (en) 2016-04-21
HRP20160334T1 (hr) 2016-05-06
RS54773B1 (sr) 2016-10-31
EP2748171A1 (en) 2014-07-02
EA022562B1 (ru) 2016-01-29
SG2014009617A (en) 2014-05-29
KR20140054007A (ko) 2014-05-08
BR112014004219B1 (pt) 2021-11-30
IL231008A0 (en) 2014-03-31
JP2014527060A (ja) 2014-10-09
DK2748171T3 (en) 2016-05-09
ZA201400387B (en) 2015-05-27
AU2012298949B2 (en) 2016-09-22
HK1196607A1 (zh) 2014-12-19
US8884023B2 (en) 2014-11-11
BR112014004219A2 (pt) 2017-03-14
JP5893738B2 (ja) 2016-03-23
HUE029390T2 (en) 2017-02-28
ES2568603T3 (es) 2016-05-03
CN103930428B (zh) 2016-05-11
CA2845149C (en) 2019-12-31
CA2845149A1 (en) 2013-02-28
PL2748171T3 (pl) 2016-06-30
CN103930428A (zh) 2014-07-16
EP2748171B1 (en) 2016-02-03
WO2013028715A1 (en) 2013-02-28
US20150018318A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
MX358463B (es) Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.
NZ601121A (en) 5-alkynyl-pyrimidines
MX351812B (es) Derivados de piridona.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2013014564A (es) Piridin-2-amidas utiles como agonistas canabinoides 2 (cb2).
PH12015501083A1 (en) Novel pyridine derivatives
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MY171831A (en) Novel fused pyrimidine compound or salt thereof
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
MX2014004920A (es) Nuevos derivados de pirazina.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
MY157423A (en) Production method of intermediate compound for synthesizing medicament
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX355654B (es) Derivado de paroxetina.
TN2011000530A1 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
IN2012DN06600A (es)
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
TN2013000075A1 (en) Production method of intermediate compound for synthesizing medicament
UA64492U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-(2'-BROMO-3'-PHENYL)ALLYLIDENEHYDRAZINOXANTHINE EXHIBITING DIURETIC ACTION
TN2011000049A1 (en) 5-alkynyl-pyrimidines

Legal Events

Date Code Title Description
FG Grant or registration